- Home
- Publications
- Publication Search
- Publication Details
Title
Approved HIV reverse transcriptase inhibitors in the past decade
Authors
Keywords
HIV treatment, HAART, NRTI, NNRTI, Clinical efficacy
Journal
Acta Pharmaceutica Sinica B
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-11-17
DOI
10.1016/j.apsb.2021.11.009
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study
- (2021) Guangdi Li et al. Aging-US
- Druggability modification strategies of the diarylpyrimidine‐type non‐nucleoside reverse transcriptase inhibitors
- (2021) Li Ding et al. MEDICINAL RESEARCH REVIEWS
- Life-long passion for antiviral research and drug development: 80th birthday of Prof. Dr. Erik De Clercq
- (2021) Guangdi Li et al. BIOCHEMICAL PHARMACOLOGY
- Avoiding Drug Resistance in HIV Reverse Transcriptase
- (2021) Maria E. Cilento et al. CHEMICAL REVIEWS
- Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday
- (2021) Guangdi Li et al. MOLECULES
- Cytoplasmic synthesis of endogenous Alu complementary DNA via reverse transcription and implications in age-related macular degeneration
- (2021) Shinichi Fukuda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study
- (2021) Annalene Nel et al. Lancet HIV
- Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study
- (2021) Jared M Baeten et al. Lancet HIV
- An overview of ProTide technology and its implications to drug discovery
- (2021) Michaela Serpi et al. Expert Opinion on Drug Discovery
- Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants
- (2021) Rima K Acosta et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- High-resolution view of HIV-1 reverse transcriptase initiation complexes and inhibition by NNRTI drugs
- (2021) Betty Ha et al. Nature Communications
- Where are we with drug treatments for covid-19?
- (2021) Chris Baraniuk BMJ-British Medical Journal
- Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
- (2021) Chloe Orkin et al. Lancet HIV
- Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial
- (2021) Jean-Michel Molina et al. Lancet HIV
- Genetic Diversity of SARS-CoV-2 over a One-Year Period of the COVID-19 Pandemic: A Global Perspective
- (2021) Miao Miao et al. Biomedicines
- Pharmacokinetic and Safety Profile of the Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV
- (2021) Wendy Ankrom et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel
- (2021) Xin Jin et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Fluoride Pharmacokinetics in Urine and Plasma Following Multiple Doses of MK‐8507, an Investigational, Oral, Once‐Weekly Non‐Nucleoside Reverse Transcriptase Inhibitor
- (2021) Gillian Gillespie et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs
- (2021) Li Ding et al. JOURNAL OF MEDICINAL CHEMISTRY
- An update on neuropsychiatric adverse effects with second-generation integrase inhibitors and nonnucleoside reverse transcriptase inhibitors
- (2021) Tessa Senneker et al. Current Opinion in HIV and AIDS
- Putative Repurposing of Lamivudine, a Nucleoside/Nucleotide Analogue and Antiretroviral to Improve the Outcome of Cancer and COVID-19 Patients
- (2021) José J. García-Trejo et al. Frontiers in Oncology
- Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week
- (2021) Dirk Schürmann et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A medicinal chemist who reshaped the antiviral drug industry: John Charles Martin (1951–2021)
- (2021) Guangdi Li et al. MEDICINAL RESEARCH REVIEWS
- Clinical significance of chemokine receptor antagonists
- (2020) Miao Miao et al. Expert Opinion on Drug Metabolism & Toxicology
- Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study
- (2020) Min Zhang et al. Hepatology International
- The pyrimidine analog FNC potently inhibits the replication of multiple enteroviruses
- (2020) Na Xu et al. JOURNAL OF VIROLOGY
- Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
- (2020) Guangdi Li et al. NATURE REVIEWS DRUG DISCOVERY
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
- (2020) Chloe Orkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
- (2020) Susan Swindells et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial
- (2020) Dirk Schürmann et al. Lancet HIV
- Prodrugs of γ‐Alkyl‐modified Nucleoside Triphosphates – improved Inhibition of HIV Reverse Transcriptase
- (2020) Chris Meier et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- The Lymphoid Tissue Pharmacokinetics of Tenofovir disoproxil fumarate and Tenofovir alafenamide in HIV‐infected Persons
- (2020) Courtney V. Fletcher et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical characteristics of older and younger patients infected with SARS-CoV-2
- (2020) Zhiguo Zhou et al. Aging-US
- Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy
- (2020) Julia del Amo et al. ANNALS OF INTERNAL MEDICINE
- Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV
- (2020) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- Mechanistic Insight into Antiretroviral Potency of 2′-Deoxy-2′-β-fluoro-4′-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention
- (2020) Li Sun et al. JOURNAL OF MEDICINAL CHEMISTRY
- Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
- (2020) Kenneth H Mayer et al. LANCET
- Clinical targeting of HIV capsid protein with a long-acting small molecule
- (2020) John O. Link et al. NATURE
- Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy
- (2020) Miao Miao et al. Drug Design Development and Therapy
- A Randomized, Open‐Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID‐19, a Pilot Study
- (2020) Zhigang Ren et al. Advanced Science
- 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0
- (2020) L Ryom et al. HIV MEDICINE
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
- (2020) Michael S. Saag et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development
- (2020) Jayakrishna Ambati et al. Nature Communications
- HIV‐1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates
- (2020) Soo‐Yon Rhee et al. Journal of the International AIDS Society
- Examining the Safety, Pharmacokinetics, and Pharmacodynamics of a Rectally Administered IQP-0528 Gel for HIV Pre-Exposure Prophylaxis: A First-In-Human Study
- (2020) Amer Al-Khouja et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
- (2020) Edgar T Overton et al. LANCET
- Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase
- (2020) Mark J. Siedner et al. Nature Communications
- Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors
- (2019) Gaetana Sterrantino et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In Vitro Evaluation of the Drug Interaction Potential of Doravirine
- (2019) Kelly Bleasby et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population Pharmacokinetics of Doravirine and Exposure-Response Analysis in Individuals with HIV-1
- (2019) Ka Lai Yee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Doravirine and the Potential for CYP3A-Mediated Drug–Drug Interactions
- (2019) Sauzanne G. Khalilieh et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Investigation of Pharmacokinetic Interactions Between Doravirine and Elbasvir/Grazoprevir and Ledipasvir/Sofosbuvir
- (2019) Wendy Ankrom et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks
- (2019) Margaret Johnson et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Fifty Years in Search of Selective Antiviral Drugs
- (2019) Erik De Clercq JOURNAL OF MEDICINAL CHEMISTRY
- Recent progress in HIV-1 inhibitors targeting the entrance channel of HIV-1 non-nucleoside reverse transcriptase inhibitor binding pocket
- (2019) Shuang-Xi Gu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Once-Weekly Oral Dosing of MK-8591 Protects Male Rhesus Macaques From Intrarectal Challenge With SHIV109CP3
- (2019) Martin Markowitz et al. JOURNAL OF INFECTIOUS DISEASES
- Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV
- (2019) Willem D.F. Venter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment
- (2019) Yali Wang et al. Expert Opinion on Drug Metabolism & Toxicology
- Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naïve HIV-1 Infected Adults with Transmitted Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance Mutations
- (2019) Alexander Wong et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs
- (2019) Dongwei Kang et al. Acta Pharmaceutica Sinica B
- Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities
- (2019) Krishnaveni Reddy et al. AIDS
- Topical Microbicides in HIV Prevention: State of the Promise
- (2019) Jared M. Baeten et al. Annual Review of Medicine
- Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women
- (2019) Cissy Kityo et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Epistasis and entrenchment of drug resistance in HIV-1 subtype B
- (2019) Avik Biswas et al. eLife
- Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial
- (2019) Franco Maggiolo et al. Lancet HIV
- Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors
- (2019) Kaijun Jin et al. Acta Pharmaceutica Sinica B
- Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): Our past twenty years
- (2019) Chunlin Zhuang et al. Acta Pharmaceutica Sinica B
- Cutting into the Substrate Dominance: Pharmacophore and Structure-Based Approaches toward Inhibiting Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease H
- (2019) Lei Wang et al. ACCOUNTS OF CHEMICAL RESEARCH
- Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults
- (2019) Scott L Letendre et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Design of an in vitro biocatalytic cascade for the manufacture of islatravir
- (2019) Mark A. Huffman et al. SCIENCE
- A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
- (2018) Joseph J. Eron et al. AIDS
- Extended Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention
- (2018) Stephanie E. Barrett et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics
- (2018) Wendy Ankrom et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections
- (2018) Erik De Clercq BIOCHEMICAL PHARMACOLOGY
- OUP accepted manuscript
- (2018) CLINICAL INFECTIOUS DISEASES
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
- (2018) Norah A. Terrault et al. HEPATOLOGY
- Brief Report
- (2018) Sally Hodder et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals
- (2018) Rebecca Begley et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- OUP accepted manuscript
- (2018) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks
- (2018) Nicolas Margot et al. JOURNAL OF CLINICAL VIROLOGY
- Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
- (2018) Josep M Llibre et al. LANCET
- Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs
- (2018) Dhwanil A. Dalwadi et al. PHARMACOLOGICAL REVIEWS
- Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans
- (2018) Rosa I. Sanchez et al. XENOBIOTICA
- Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial
- (2018) Chloe Orkin et al. Lancet HIV
- Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
- (2018) Jean-Michel Molina et al. Lancet HIV
- Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
- (2018) Jean-Michel Molina et al. Lancet HIV
- Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
- (2018) Eric S Daar et al. Lancet HIV
- HIV Antiretroviral Pre-Exposure Prophylaxis: Development Challenges and Pipeline Promise
- (2018) Craig W. Hendrix CLINICAL PHARMACOLOGY & THERAPEUTICS
- Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients
- (2018) Cathia Soulie et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial
- (2018) Joseph J Eron et al. Lancet HIV
- Intestinal absorption mechanisms of 2′-deoxy-2′-β-fluoro-4′-azidocytidine, a cytidine analog for AIDS treatment, and its interaction with P-glycoprotein, multidrug resistance-associated protein 2 and breast cancer resistance protein
- (2017) Yixian Liu et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
- (2017) Pietro Lampertico et al. JOURNAL OF HEPATOLOGY
- Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment–Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide
- (2017) Nicolas A. Margot et al. JOURNAL OF INFECTIOUS DISEASES
- The ProTide Prodrug Technology: From the Concept to the Clinic
- (2017) Youcef Mehellou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
- (2017) David A Margolis et al. LANCET
- Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
- (2017) Paul E Sax et al. LANCET
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
- (2017) Joel Gallant et al. LANCET
- Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial
- (2017) Paul E Sax et al. Lancet HIV
- Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
- (2017) Edwin DeJesus et al. Lancet HIV
- Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
- (2017) Chloe Orkin et al. Lancet HIV
- Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment
- (2016) Joseph M. Custodio et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations
- (2016) Meizhen Feng et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals on Failing First-Line Antiretroviral Therapy in South Africa
- (2016) Kerri J. Penrose et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)
- (2016) Erik De Clercq BIOCHEMICAL PHARMACOLOGY
- Approved Antiviral Drugs over the Past 50 Years
- (2016) Erik De Clercq et al. CLINICAL MICROBIOLOGY REVIEWS
- Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals
- (2016) Julia L. Marcus et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Rilpivirine and Doravirine have complementary efficacies against NNRTI-Resistant HIV-1 mutants
- (2016) Steven J. Smith et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment
- (2016) Anton Pozniak et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel
- (2016) Barbara A. Friedland et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics
- (2016) Sauzanne Khalilieh et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
- (2016) Anthony Mills et al. LANCET INFECTIOUS DISEASES
- The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy
- (2016) Huilian Wang et al. MEDICINE
- Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women
- (2016) Annalene Nel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
- (2016) Jared M. Baeten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel antiretroviral agents and universal access to HIV care
- (2016) Mark A Boyd et al. Lancet HIV
- Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
- (2016) Nicholas T. Funderburg et al. EBioMedicine
- In VitroVirology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate
- (2015) Christian Callebaut et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Oral Administration of the Nucleoside EFdA (4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine) Provides Rapid Suppression of HIV Viremia in Humanized Mice and Favorable Pharmacokinetic Properties in Mice and the Rhesus Macaque
- (2015) Cheryl A. Stoddart et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention
- (2015) Anthony S. Ham et al. ANTIVIRAL RESEARCH
- Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
- (2015) S. K. Sarin et al. Hepatology International
- Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings
- (2015) Beatrice A. Chen et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy
- (2015) Anthony Mills et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancy
- (2015) Shweta R. Ugaonkar et al. JOURNAL OF CONTROLLED RELEASE
- Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
- (2015) Paul E Sax et al. LANCET
- An integrated map of HIV genome-wide variation from a population perspective
- (2015) Guangdi Li et al. Retrovirology
- An Odyssey in antiviral drug development—50 years at the Rega Institute: 1964–2014
- (2015) Erik De Clercq Acta Pharmaceutica Sinica B
- A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women
- (2014) Annalene Nel et al. AIDS
- Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults
- (2014) Calvin Cohen et al. AIDS
- In VitroResistance Selection with Doravirine (MK-1439), a Novel Nonnucleoside Reverse Transcriptase Inhibitor with Distinct Mutation Development Pathways
- (2014) Meizhen Feng et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects
- (2014) Matt S Anderson et al. ANTIVIRAL THERAPY
- Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy
- (2014) Paul E. Sax et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- 4′-Ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) Inhibits HIV-1 Reverse Transcriptase with Multiple Mechanisms
- (2014) Eleftherios Michailidis et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Quantification of 2′-deoxy-2′-β-fluoro-4′-azidocytidine in rat and dog plasma using liquid chromatography-quadrupole time-of-flight and liquid chromatography-triple quadrupole mass spectrometry: Application to bioavailability and pharmacokinetic studies
- (2014) Youmei Peng et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Azvudine, A Novel Nucleoside Reverse Transcriptase Inhibitor Showed Good Drug Combination Features and Better Inhibition on Drug-Resistant Strains than Lamivudine In Vitro
- (2014) Rui-Rui Wang et al. PLoS One
- Evaluation of Combinations of 4′-Ethynyl-2-Fluoro-2′-Deoxyadenosine with Clinically Used Antiretroviral Drugs
- (2013) Atsuko Hachiya et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroCharacterization of MK-1439, a Novel HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor
- (2013) Ming-Tain Lai et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Development of dapivirine vaginal ring for HIV prevention
- (2013) Bríd Devlin et al. ANTIVIRAL RESEARCH
- Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses
- (2013) Bernard Côté et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults
- (2013) Peter J. Ruane et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Response of Simian Immunodeficiency Virus to the Novel Nucleoside Reverse Transcriptase Inhibitor 4′-Ethynyl-2-Fluoro-2′-DeoxyadenosineIn VitroandIn Vivo
- (2012) Michael Murphey-Corb et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340,In Vitro
- (2012) Eve-Irene Lepist et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Novel nucleoside analogue FNC is effective against both wild-type and lamivudine-resistant hepatitis B virus clinical isolates
- (2012) Yubing Zhou et al. ANTIVIRAL THERAPY
- Mechanism for Effective Lymphoid Cell and Tissue Loading Following Oral Administration of Nucleotide Prodrug GS-7340
- (2012) Darius Babusis et al. MOLECULAR PHARMACEUTICS
- In VitroResistance Profile of the Candidate HIV-1 Microbicide Drug Dapivirine
- (2011) Susan M. Schader et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Vaginal Microbicide Gel for Delivery of IQP-0528, a Pyrimidinedione Analog with a Dual Mechanism of Action against HIV-1
- (2011) Alamelu Mahalingam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase
- (2011) Robert Gomez et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The Nonnucleoside Reverse Transcriptase Inhibitor MIV-150 in Carrageenan Gel Prevents Rectal Transmission of Simian/Human Immunodeficiency Virus Infection in Macaques
- (2011) R. Singer et al. JOURNAL OF VIROLOGY
- Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
- (2011) Jean-Michel Molina et al. LANCET
- Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation
- (2010) G. van 't Klooster et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
- (2010) Robert M. Grant et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Availability of Dapivirine (TMC120) Delivered from an Intravaginal Ring
- (2009) J. Romano et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1
- (2009) H. Azijn et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety and Pharmacokinetics of Dapivirine Delivery From Matrix and Reservoir Intravaginal Rings to HIV-Negative Women
- (2009) Annalene Nel et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- The Design, Synthesis, and Antiviral Activity of Monofluoro and Difluoro Analogues of 4′-Azidocytidine against Hepatitis C Virus Replication: The Discovery of 4′-Azido-2′-deoxy-2′-fluorocytidine and 4′-Azido-2′-dideoxy-2′,2′-difluorocytidine
- (2009) David B. Smith et al. JOURNAL OF MEDICINAL CHEMISTRY
- The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations
- (2008) Thomas J. Tucker et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- 2′-Deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants
- (2008) Atsushi Kawamoto et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Discovery of 3-{5-[(6-Amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): A Potent, Orally Bioavailable HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor with Improved Potency against Key Mutant Viruses
- (2008) Thomas J. Tucker et al. JOURNAL OF MEDICINAL CHEMISTRY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More